PDM08 Clinical Trial in Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

June 30, 2012

Study Completion Date

January 31, 2013

Conditions
Malignant Solid Tumours
Interventions
DRUG

PDM08

To assess the tolerability and safety of increasing multiple doses administration of PDM08: 560 μg, 1.12, 2.24, 3.5, 14, 28 and 56 mg administered twice a week for four weeks in patients with advanced solid tumours for which there is no standard therapy or they are refractory to it.

Trial Locations (1)

28046

Hospital Universitario La Paz, Madrid

All Listed Sponsors
lead

Prodimed S.A.

OTHER

NCT01380249 - PDM08 Clinical Trial in Advanced Solid Tumors | Biotech Hunter | Biotech Hunter